Pfizer, Bristol-Myers’ Eliquis Recommended by U.K. Cost Agency
This article is for subscribers only.
Pfizer Inc. and Bristol-Myers Squibb Co.’s blood-thinner apixaban won a final recommendation from the U.K.’s health-cost agency.
The pill, also known by the brand name Eliquis, may be used to prevent blood clots in adults who have undergone hip or knee replacement surgery, the National Institute for Health and Clinical Excellence said in a statement today. The agency, known as NICE, advises the state-run National Health Service on which treatments represent value for money.